Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 30, 2020
ProBioGen announced the closing of a master service agreement with Asahi Kasei Pharma.
read more
Monday, December 13, 2021
Ascensus Specialties announced its acquisition of Wychem Limited, a UK-based manufacturer of fine chemicals for pharmaceutical and specialty applications. This transaction complements Ascensus’ existing capabilities and reinforces the Company’s focus...
read more
Monday, February 11, 2013
Ash Stevens Inc. (ASI), a full service contract pharmaceutical manufacturer, is in the final stages of completing a multi-year, multi-million dollar expansion to its cGMP manufacturing facility in Riverview, Michigan. All construction on the project ...
read more
Tuesday, December 29, 2015
Ash Stevens’ Riverview manufacturing facility is pleased to announce it has been recognized for exemplary efforts in improving its environmental, health, safety and security (EHS&S) operations by the Society of Chemical Manufacturers and Affiliates (...
read more
(BUSINESS WIRE) – Ash Stevens, Inc., a leading provider of global contract pharmaceutical drug substance development and active pharmaceutical ingredient (API) manufacturing services, is pleased to announce receipt of a 2014 Lilly Global Supplier ...
read more
Wednesday, January 28, 2015
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, is pleased to announce the U.S Food and Drug Administration (FDA) has approved...
read more
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, announces the U.S. Food and Drug Administration (FDA) has approved ASI's ...
read more
Ashland completed the expansion of its Viatel bioresorbable polymer manufacturing site and has relocated R&D from Dublin to the National Science Park, Ireland.
read more
Astellas Pharma Inc. announced that the FDA has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants.
read more
Avania, a full-service global MedTech contract research organization (“CRO”), announced that Astorg has acquired a majority stake in the company.
read more
Astorg and International Chemical Investors Group (ICIG) have signed a binding agreement whereby Astorg will acquire CordenPharm from ICIG. As part of the transaction, the founders will take the opportunity to reinvest as partners with Astorg.
read more
Monday, September 20, 2021
Astrea Bioseparations, a leading provider of bioseparations products and services, announced two new investments to enhance operations and customer support resources. The investments include an expansion of the company’s research and development ...
read more
Astrix, the laboratory digital transformation experts, announced the launch of a dedicated Digital Quality & Compliance practice at the company. This targeted services practice delivers the expertise & guidance to help organizations supercharge their...
read more
Tuesday, September 21, 2021
Asymchem announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration.
read more
Asymchem announced its Tianjin1 site successfully completed a FDA general GMP reinspection conducted between January 14-18, 2019. No Form 483 was issued.
read more